| Bioactivity | HS-1793 is a Resveratrol (HY-16561) analogue with antitumor activities in a variety of cancer cell lines[1]. HS-1793 induces cell apoptosis[2]. |
| Invitro | HS-1793 (0-100 µM; 24 h) suppresses proliferation of MCF-7, MDA-MB-231 and HCT116 cells[1][2].HS-1793 (0-50 µM; 4 h) inhibits hypoxia-induced HIF-1α protein in MCF-7 and MDA-MB-231 cells unrelated to cell death, downregulates hypoxia-induced VEGF expression, and suppresses hypoxia-induced mRNA expression of VEGF at the transcriptional level[1].HS-1793 (0-100 µM; 24 h) induces apoptosis, promotes G2/M cell cycle arrest, and inhibits Akt and ERK phosphorylation in HCT116 cells[2]. Cell Proliferation Assay[1] Cell Line: |
| In Vivo | HS-1793 (5 and 10 mg/kg; i.p.; twice a week, 4 weeks) significantly inhibits MDA-MB-231 xenograft tumor growth and in a dose-dependent manner and relatively hampers angiogenesis with non-toxicity[1]. Animal Model: |
| Name | HS-1793 |
| CAS | 927885-00-5 |
| Formula | C16H12O3 |
| Molar Mass | 252.26 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Kim DH, et al. HS-1793, a resveratrol analogue, downregulates the expression of hypoxia-induced HIF-1 and VEGF and inhibits tumor growth of human breast cancer cells in a nude mouse xenograft model. Int J Oncol. 2017 Aug;51(2):715-723. [2]. Kim DH, et al. Resveratrol analogue, HS-1793, induces apoptotic cell death and cell cycle arrest through downregulation of AKT in human colon cancer cells. Oncol Rep. 2017 Jan;37(1):281-288. |